News
AYTU
2.050
0.00%
0.000
Weekly Report: what happened at AYTU last week (0928-1002)?
Weekly Report · 2d ago
Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 09/30 12:22
Aytu BioPharma Price Target Raised to $15.00/Share From $14.50 by Ascendiant Capital
Dow Jones · 09/30 10:06
Aytu BioPharma Is Maintained at Buy by Ascendiant Capital
Dow Jones · 09/30 10:06
Ascendiant Capital Maintains Buy on Aytu BioPharma, Raises Price Target to $15
Benzinga · 09/30 09:56
Aytu BioScience Earnings Call Highlights EXXUA Momentum
TipRanks · 09/29 00:10
Weekly Report: what happened at AYTU last week (0921-0925)?
Weekly Report · 09/28 09:27
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Surrozen (SRZN) and aTyr Pharma (ATYR)
TipRanks · 09/24 15:21
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX) and Aytu BioScience (AYTU)
TipRanks · 09/23 13:20
Transcript: Aytu BioPharma Q4 2026 Earnings Conference Call
Benzinga · 09/22 21:16
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
NASDAQ · 09/22 21:15
Aytu BioPharma reports Q4 EPS 0c, consensus (35c)
TipRanks · 09/22 20:15
Aytu BioPharma GAAP EPS of $0.00 beats by $0.33, revenue of $16.1M beats by $3.82M
Seeking Alpha · 09/22 20:12
Aytu BioPharma Q4 EPS $0.00 and Sales $16.106M Beat $12.276M Estimate
Benzinga · 09/22 20:06
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results
Barchart · 09/22 15:05
Here are the major earnings after the close Tuesday
Seeking Alpha · 09/22 14:00
Earnings Scheduled For September 22, 2026
Benzinga · 09/22 11:11
Aytu BioPharma Q4 2026 Earnings Preview
Seeking Alpha · 09/21 21:35
Weekly Report: what happened at AYTU last week (0914-0918)?
Weekly Report · 09/21 09:27
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026
Barchart · 09/16 15:30
More
Webull provides a variety of real-time AYTU stock news. You can receive the latest news about Aytu Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About AYTU
Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.